Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glimepiride · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Glimepiride Tablets 1 mg |
| 2 | ACTIVE_COMPARATOR | Amaryl® Tablets 1 mg |
| Name | Type | Description |
|---|---|---|
| Glimepiride Tablets 1 mg | DRUG | 1mg, single dose fasting |
| Amaryl® Tablets 1 mg | DRUG | 1mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. a. Women of childbearing potential must have a negative serum (Beta HCG) pregnancy test performed within 14 days prior to the start of the study and on the evening prior to each dose administrati...
Glimepiride is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is also known as Glimepiride Tablets 1 mg. The listed development stage is Phase 1, and the clinical program includes two completed Phase 1 trials conducted in the United States.
Glimepiride targets KCNJ11 and ABCC8. It is classified as a blocker of these targets. Both targets are part of the ATP-sensitive potassium channel complex, and the drug acts through this molecular target class according to the available drug profile information.
Glimepiride is developed by Viatris Inc., which trades under the ticker VTRS. The company is listed as the developer of the Glimepiride Tablets 1 mg program, which includes two completed Phase 1 clinical trials.
Glimepiride is in Phase 1 development. Both listed trials are Phase 1 studies, and both have completed status. The program has no active trials at this time, with a total of two completed trials and 80 enrolled participants across the program.
Glimepiride has been studied in two completed Phase 1 trials: NCT00650533, a food study of Glimepiride Tablets 1 mg versus Amaryl Tablets 1 mg, and NCT00648362, a fasting study of the same comparison. Both enrolled 40 healthy volunteers in the United States.